TABLE OF CONTENTS
1. EXECUTIVE SUMMARY
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3.Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2.Breakdown of Primary Respondents
3.5. Forecasting Model
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Value Chain Analysis
5.2. Porterโs Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis
6. ALLERGY TREATMENT MARKET, BY TYPE
6.1. Overview
6.2. Eye Allergy
6.3. Rhinitis
6.4. Asthma
6.5. Skin Allergy
6.6. Food Allergy
6.7. Other Allergies
7. ALLERGY TREATMENT MARKET, BY TREATMENT
7.1. Overview
7.2. Anti-allergy Drugs
7.3. Immunotherapy
8. ALLERGY TREATMENT MARKET, BY REGION
8.1. Overview
8.1. North America
8.1.1. US
8.1.2. Canada
8.2. Europe
8.2.1. Germany
8.2.2. France
8.2.3. UK
8.2.4. Italy
8.2.5. Spain
8.2.6. Rest of Europe
8.3. Asia-Pacific
8.3.1. China
8.3.2. India
8.3.3. Japan
8.3.4. South Korea
8.3.5. Australia
8.3.6. Rest of Asia-Pacific
8.4. Rest of the World
8.4.1. Middle East
8.4.2. Africa
8.4.3. Latin America
9. COMPETITIVE LANDSCAPE
9.1. Overview
9.2. Competitive Analysis
9.3. Market Share Analysis
9.4. Major Growth Strategy in the Allergy Treatment Market,
9.5. Competitive Benchmarking
9.6. Leading Players in Terms of Number of Developments in the Allergy treatment Market,
9.7. Key Developments and Growth Strategies
9.7.1. New Product Launch/Service Deployment
9.7.2. Merger & Acquisitions
9.7.3. Joint Ventures
9.8. Major Players Financial Matrix
9.8.1. Sales & Operating Income, 2022
9.8.2. Major Players R&D Expenditure. 2022
10. COMPANY PROFILES
10.1. Akorn, Incorporated (US)
10.1.1. Company Overview
10.1.2. Financial Overview
10.1.3. Products Offered
10.1.4. Key Developments
10.1.5. SWOT Analysis
10.1.6. Key Strategies
10.2. Pfizer Inc. (US)
10.2.1. Company Overview
10.2.2. Financial Overview
10.2.3. Products Offered
10.2.4. Key Developments
10.2.5. SWOT Analysis
10.2.6. Key Strategies
10.3. GlaxoSmithKline plc (UK)
10.3.1. Company Overview
10.3.2. Financial Overview
10.3.3. Products Offered
10.3.4. Key Developments
10.3.5. SWOT Analysis
10.3.6. Key Strategies
10.4. Novartis AG (Switzerland)
10.4.1. Company Overview
10.4.2. Financial Overview
10.4.3. Products Offered
10.4.4. Key Developments
10.4.5. SWOT Analysis
10.4.6. Key Strategies
10.5. Mylan N.V. (US)
10.5.1. Company Overview
10.5.2. Financial Overview
10.5.3. Products Offered
10.5.4. Key Developments
10.5.5. SWOT Analysis
10.5.6. Key Strategies
10.6. Teva Pharmaceutical Industries Ltd. (Israel)
10.6.1. Company Overview
10.6.2. Financial Overview
10.6.3. Products Offered
10.6.4. Key Developments
10.6.5. SWOT Analysis
10.6.6. Key Strategies
10.7. Sanofi (France)
10.7.1. Company Overview
10.7.2. Financial Overview
10.7.3. Products Offered
10.7.4. Key Developments
10.7.5. SWOT Analysis
10.7.6. Key Strategies
10.8. BOEHRINGER INGELHEIM INTERNATIONAL GMBH. (GERMANY)
10.8.1. Company Overview
10.8.2. Financial Overview
10.8.3. Products Offered
10.8.4. Key Developments
10.8.5. SWOT Analysis
10.8.6. Key Strategies
10.9. AstraZeneca (UK)
10.9.1. Company Overview
10.9.2. Financial Overview
10.9.3. Products Offered
10.9.4. Key Developments
10.9.5. SWOT Analysis
10.9.6. Key Strategies
10.10. Johnson & Johnson Private Limited (US)
10.10.1. Company Overview
10.10.2. Financial Overview
10.10.3. Products Offered
10.10.4. Key Developments
10.10.5. SWOT Analysis
10.10.6. Key Strategies
10.11. Bayer AG (Germany)
10.11.1. Company Overview
10.11.2. Financial Overview
10.11.3. Products Offered
10.11.4. Key Developments
10.11.5. SWOT Analysis
10.11.6. Key Strategies
10.12. Merck & Co., Inc. (US)
10.12.1. Company Overview
10.12.2. Financial Overview
10.12.3. Products Offered
10.12.4. Key Developments
10.12.5. SWOT Analysis
10.12.6. Key Strategies
11. APPENDIX
11.1. References
11.2. Related Reports
LIST OF TABLES
TABLE 1 ALLERGY TREATMENT MARKET, SYNOPSIS, 2018-2032
TABLE 2 ALLERGY TREATMENT MARKET, ESTIMATES & FORECAST, 2018-2032 (USD BILLION)
TABLE 3 ALLERGY TREATMENT MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 4 ALLERGY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 5 NORTH AMERICA: ALLERGY TREATMENT MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 6 NORTH AMERICA: ALLERGY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 7 US: ALLERGY TREATMENT MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 8 US: ALLERGY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 9 CANADA: ALLERGY TREATMENT MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 10 CANADA: ALLERGY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 1 EUROPE: ALLERGY TREATMENT MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 2 EUROPE: ALLERGY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 3 GERMANY: ALLERGY TREATMENT MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 4 GERMANY: ALLERGY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 5 FRANCE: ALLERGY TREATMENT MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 6 FRANCE: ALLERGY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 7 ITALY: ALLERGY TREATMENT MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 8 ITALY: ALLERGY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 9 SPAIN: ALLERGY TREATMENT MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 10 SPAIN: ALLERGY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 11 UK: ALLERGY TREATMENT MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 12 UK: ALLERGY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 13 REST OF EUROPE: ALLERGY TREATMENT MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 14 REST OF EUROPE: ALLERGY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 15 ASIA-PACIFIC: ALLERGY TREATMENT MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 16 ASIA-PACIFIC: ALLERGY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 17 JAPAN: ALLERGY TREATMENT MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 18 JAPAN: ALLERGY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 19 CHINA: ALLERGY TREATMENT MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 20 CHINA: ALLERGY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 21 INDIA: ALLERGY TREATMENT MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 22 INDIA: ALLERGY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 23 AUSTRALIA: ALLERGY TREATMENT MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 24 AUSTRALIA: ALLERGY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 25 SOUTH KOREA: ALLERGY TREATMENT MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 26 SOUTH KOREA: ALLERGY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 27 REST OF ASIA-PACIFIC: ALLERGY TREATMENT MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 28 REST OF ASIA-PACIFIC: ALLERGY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 29 REST OF THE WORLD: ALLERGY TREATMENT MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 30 REST OF THE WORLD: ALLERGY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 31 MIDDLE EAST: ALLERGY TREATMENT MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 32 MIDDLE EAST: ALLERGY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 33 AFRICA: ALLERGY TREATMENT MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 34 AFRICA: ALLERGY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 35 LATIN AMERICA: ALLERGY TREATMENT MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 36 LATIN AMERICA: ALLERGY TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE ALLERGY TREATMENT MARKET
FIGURE 3 MARKET DYNAMICS FOR THE ALLERGY TREATMENT MARKET
FIGURE 4 ALLERGY TREATMENT MARKET, SHARE (%), BY TYPE, 2022
FIGURE 5 ALLERGY TREATMENT MARKET, SHARE (%), BY TREATMENT, 2022
FIGURE 6 ALLERGY TREATMENT MARKET, SHARE (%), BY REGION, 2022
FIGURE 7 NORTH AMERICA: ALLERGY TREATMENT MARKET, SHARE (%), BY REGION, 2022
FIGURE 8 EUROPE: ALLERGY TREATMENT MARKET, SHARE (%), BY REGION, 2022
FIGURE 9 ASIA-PACIFIC: ALLERGY TREATMENT MARKET, SHARE (%), BY REGION, 2022
FIGURE 10 REST OF THE WORLD: ALLERGY TREATMENT MARKET, SHARE (%), BY REGION, 2022
FIGURE 11 ALLERGY TREATMENT MARKET: COMPANY SHARE ANALYSIS, 2022 (%)
FIGURE 12 AKORN, INCORPORATED (US): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 13 AKORN, INCORPORATED (US): SWOT ANALYSIS
FIGURE 14 PFIZER INC. (US): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 15 PFIZER INC. (US): SWOT ANALYSIS
FIGURE 16 GLAXOSMITHKLINE PLC (UK): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 17 GLAXOSMITHKLINE PLC (UK): SWOT ANALYSIS
FIGURE 18 NOVARTIS AG (SWITZERLAND): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 19 NOVARTIS AG (SWITZERLAND): SWOT ANALYSIS
FIGURE 20 MYLAN N.V. (US).: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 21 MYLAN N.V. (US).: SWOT ANALYSIS
FIGURE 22 TEVA PHARMACEUTICAL INDUSTRIES LTD. (ISRAEL): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 23 TEVA PHARMACEUTICAL INDUSTRIES LTD. (ISRAEL): SWOT ANALYSIS
FIGURE 24 SANOFI (FRANCE): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 25 SANOFI (FRANCE): SWOT ANALYSIS
FIGURE 26 BOEHRINGER INGELHEIM INTERNATIONAL GMBH. (GERMANY): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 27 BOEHRINGER INGELHEIM INTERNATIONAL GMBH. (GERMANY): SWOT ANALYSIS
FIGURE 28 ASTRAZENECA (UK): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 29 ASTRAZENECA (UK): SWOT ANALYSIS
FIGURE 30 JOHNSON & JOHNSON PRIVATE LIMITED (US): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 31 JOHNSON & JOHNSON PRIVATE LIMITED (US): SWOT ANALYSIS
FIGURE 32 BAYER AG (GERMANY): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 33 BAYER AG (GERMANY): SWOT ANALYSIS
FIGURE 34 MERCK & CO., INC. (US): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 35 MERCK & CO., INC. (US): SWOT ANALYSIS